重组人5型腺病毒注射液在肝癌介入治疗中的疗效探讨

An investigation on the curative effect of human recombinant adenovirus type 5 injection on the interventional therapy of primary liver cancer

目的探讨重组人5型腺病毒在肝癌介入治疗中的疗效。方法选择2008-2015年间青岛市市立医院收治明确诊断的中晚期肝癌患者960例，随机分为观察组和对照组（每组各480例）。对照组在数字减影血管造影（DSA）设备引导下行肝动脉化疗剂与栓塞剂灌注，观察组在此基础上给予重组人5型腺病毒注射液（5支）。结果观察组的总有效率和AFP转阴率均较单纯采用TACE治疗的对照组高，差异有统计学意义（P〈0．05）。观察组与治疗组均无明显不良反应。结论重组人5型腺病毒联合TACE治疗中晚期肝癌为一种更加有效的治疗方法。

Objective To investigate the role of human recombinant adenovirus type 5 in the curative effect of interventional therapy of liver cancer. Methods 960 patients which were diagnosised obviously for terminal liver cancer from Qingdao Municipal Hospital between 2008 and 2015 were selected. These patients were randomly divided into 2 groups, the observation group and the control group（480 cases in each group） which were both performed with transcather hepatic arterial chemoembolization（TACE） treatment, the observation group added human recombinant adenovirus type 5. Results Total effective rate of the observation group was obviously higher than that of the control group, and the difference has statistical significance （P〈0.05）, the positive rate of AFP in the patients after treatment of the observation group was obviously lower than that of the control group, and the difference has statistical significance（P〈0.05）. The incidence of adverse reactions in the two groups had no obvious differences. Conclusion Human recombinant adenovirus type 5 combined with transcatheter hepatic arterial chemoembolization is a more effective method for the treatment of the patients with metaphase and terminal liver cancer.